205,000 Shares in CytomX Therapeutics, Inc. $CTMX Bought by Stonepine Capital Management LLC

Stonepine Capital Management LLC acquired a new stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 205,000 shares of the biotechnology company’s stock, valued at approximately $768,750. Stonepine Capital Management LLC owned about 0.09% of CytomX Therapeutics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CTMX. Wells Fargo & Company MN boosted its holdings in CytomX Therapeutics by 83.2% in the 4th quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 3,000 shares during the last quarter. Invesco Ltd. acquired a new position in CytomX Therapeutics in the second quarter worth approximately $32,000. Goldman Sachs Group Inc. bought a new position in shares of CytomX Therapeutics in the first quarter valued at approximately $39,000. May Hill Capital LLC bought a new stake in CytomX Therapeutics during the 4th quarter worth approximately $46,000. Finally, Nierenberg Investment Management Company LLC acquired a new stake in shares of CytomX Therapeutics during the second quarter worth $47,081. 67.77% of the stock is currently owned by institutional investors.

CytomX Therapeutics Stock Performance

Shares of CytomX Therapeutics stock traded down $0.21 during trading on Friday, hitting $3.21. The company’s stock had a trading volume of 2,173,251 shares, compared to its average volume of 4,851,431. CytomX Therapeutics, Inc. has a 52 week low of $1.90 and a 52 week high of $8.21. The company has a fifty day simple moving average of $3.45 and a two-hundred day simple moving average of $4.04. The company has a market capitalization of $699.46 million, a PE ratio of -6.42 and a beta of 2.12.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The firm had revenue of $1.42 million during the quarter, compared to analysts’ expectations of $12.39 million. CytomX Therapeutics had a negative return on equity of 38.46% and a negative net margin of 435.21%. As a group, analysts predict that CytomX Therapeutics, Inc. will post -0.4 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Zacks Research lowered shares of CytomX Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Wolfe Research started coverage on CytomX Therapeutics in a research note on Tuesday, May 19th. They issued an “outperform” rating and a $6.00 price target for the company. Guggenheim decreased their price target on shares of CytomX Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Wall Street Zen cut shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 23rd. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of CytomX Therapeutics in a report on Tuesday, June 16th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $11.90.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.